Protocols

Based on the limited literature available, specific dosing protocols for the combination of CJC-1295 + Ipamorelin + AOD-9604 are not well-established in peer-reviewed research. The evidence for this particular three-compound combination is extremely limited.

Individual Component Dosing (from limited literature):

The available sports medicine literature suggests that when these peptides are used individually or in combinations, dosing typically involves:

Administration route: Subcutaneous injection
Timing: Often administered in the evening or before sleep to align with natural growth hormone release patterns
Frequency: Multiple times per week rather than daily

However, the specific dosing ranges, optimal ratios between compounds, cycle lengths, and safety monitoring protocols for this three-peptide combination are not established in the peer-reviewed literature.

Evidence Limitations:

The current evidence base consists primarily of review articles discussing peptide therapies in sports medicine and orthopedic applications. No controlled clinical trials specifically examining this combination therapy were identified. The safety profile, optimal dosing, and efficacy of combining these three peptides has not been systematically studied.

Important Disclaimer:

This information is not personalized medical advice and should not be used to guide treatment decisions. Any consideration of peptide therapy should involve consultation with a qualified healthcare provider who can assess individual medical history, current health status, potential contraindications, and provide appropriate medical supervision. The use of these compounds may be subject to regulatory restrictions in many jurisdictions.

CJC-1295 + Ipamorelin + AOD-9604

Member access required